旧金山 - 专注于靶向蛋白降解疗法的生物制药公司Nurix Therapeutics, Inc. (NASDAQ: NRIX )宣布任命Roy D. Baynes博士加入其董事会。Baynes博士是血液学和肿瘤学领域的资深专家，在制药和生物技术领域拥有超过20年的临床领导经验。根据 InvestingPro 数据显示，该公司目前市值约10亿美元，资产负债表显示现金储备超过债务。

There was a time, especially in the South, when just about everyone had a Roy D. Mercer tape floating around. And, honestly, those tapes — featuring Roy D. calling folks up asking them ‘How bi ...

Shapiro, Roy D., and Bruce Isaacson. "Bose Corporation: The JIT II Program (A), (B), (C), (D), and Videotape TN." Harvard Business School Teaching Note 695-017 ...

Roy Mitchell, Psy.D., is a post-doctoral fellow with training and experience working with individuals with known or suspected neurologic disorders, severe mental illness, mood disorders ...